Moderna & Merck Shares Soar on Cancer Vaccine Breakthrough

Moderna and Merck's mRNA cancer vaccine has shown positive results in a late-stage melanoma trial, sending their shares soaring. The vaccine could be available as soon as next year if regulators approve it.

Moderna's shares surged as much as 160% following the results, with investors reacting positively to the medical breakthrough.

The mRNA technology used in the vaccine is a key area of research for both companies, and this trial represents a significant step forward in the development of cancer treatments.